Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment

Seminars in Arthritis and Rheumatism

Volumn 47, Issue 1, 2017, Pages 102-107

  Cho, Soo Kyung ^a,b   Kim, Dam ^a,b   Won, Soyoung ^b   Han, Minkyung ^b   Lee, Jiyoung ^b   Jang, Eun Jin ^c   Kim, Tae Hyung ^d   Bae, Sang Cheol ^a,b   Sung, Yoon Kyoung ^a,b  

^a Hanyang University Hospital for Rheumatic Diseases   (South Korea)

^b Clinical Research Center for Rheumatoid Arthritis   (South Korea)

^c Andong National University   (South Korea)

^d Hanyang University Guri Hospital   (South Korea)

Author keywords

Biologic DMARDs; Rheumatoid arthritis; TNF inhibitor; Tuberculosis

Indexed keywords

ABATACEPT; ADALIMUMAB; CORTICOSTEROID DERIVATIVE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; ETHAMBUTOL; GOLIMUMAB; INFLIXIMAB; ISONIAZID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZINAMIDE; RIFAMPICIN; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SOUTH KOREAN; TUBERCULOSIS; AGE; AGED; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMORBIDITY; MIDDLE AGED; RECURRENT DISEASE; RISK FACTOR; SEX FACTOR;

AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CASE-CONTROL STUDIES; COHORT STUDIES; COMORBIDITY; ETANERCEPT; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; SEX FACTORS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85012937820     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2017.01.004     Document Type: Article

References (30)

1. Walls, R.S., Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8 (2008), 601–611.
2. Tubach, F., Salmon, D., Ravaud, P., Allanore, Y., Goupille, P., Bréban, M., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy the three-year prospective French research Axed on tolerance of biotherapies registry. Arthritis Rheum 60 (2009), 1884–1894.
3. Dixon, W.G., Hyrich, K.L., Watson, K.D., Lunt, M., Galloway, J., Ustianowski, A., Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69 (2010), 522–528.
4. Gomez-Reino, J.J., Carmona, L., Valverde, V.R., Mola, E.M., Montero, M.D., Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48 (2003), 2122–2127.
5. Askling, J., Fored, C.M., Brandt, L., Baecklund, E., Bertilsson, L., Cöster, L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52 (2005), 1986–1992.
6. Winthrop, K.L., Baxter, R., Liu, L., Varley, C.D., Curtis, J.R., Baddley, J.W., et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 72 (2013), 37–42.
7. WHO. Global tuberculosis control. Surveillance, planning, financing. [Monograph on the Internet, accessed January 3, 2007]. Available from: 〈http://www.who.int/tb/publications/global_report/en/〉.
8. Seong, S.S., Choi, C.B., Woo, J.H., Bae, K.W., Joung, C.L., Uhm, W.S., et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 34 (2007), 706–711.
9. Mariette, X., Salmon, D., Group, R., French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis, 62, 2003, 791.
10. Kavanagh, P.M., Gilmartin, J.J., O'Donnell, J., O'Flanagan, D., Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee. Ir Med J 101 (2008), 6–7.
11. Solovic, I., Sester, M., Gomez-Reino, J.J., Rieder, H.L., Ehlers, S., Milburn, H.J., et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36 (2010), 1185–1206.
12. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax, 60, 2005, 800.
13. Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor alpha-California, 2002–2003. MMWR Morb Mortal Wkly Rep 53 (2004), 683–686.
14. Kim, Y.J., Kim, Y.G., Shim, T.S., Koo, B.S., Hong, S., Lee, C.K., et al. Safety of resuming tumour necrosis factor inhibitors in patients who developed tuberculosis as a complication of previous TNF inhibitors. Rheumatology 53 (2014), 1477–1481.
15. Suh, Y.S., Kwok, S., Ju, J.H., Park, K.S., Park, S.H., Yoon, C.H., et al. Safe re-administration of tumor necrosis factor-alpha (TNFα) Inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy. J Korean Med Sci 29 (2014), 38–42.
16. Kim, L., Kim, J.A., Kim, S., A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health, 36, 2014, e2014008.
17. Gomez-Reino, J.J., Carmona, L., Angel Descalzo, M., Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57 (2007), 756–761.
18. Kim, J.H., Cho, S.K., Han, M., Choi, C.B., Kim, T.H., Jun, J.B., et al. Factors influencing discrepancies between the QuantiFERON-TB gold in tube test and the tuberculin skin test in Korean patients with rheumatic diseases. Semin Arthritis Rheum 42 (2013), 424–432.
19. Joint Committee for the Revision of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention, Korean Guidelines for Tuberculosis. first ed. Seoul; 2011.
20. Bartalesi, F., Vicidomini, S., Goletti, D., Fiorelli, C., Fiori, G., Melchiorre, D., et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 33 (2009), 586–593.
21. Sung, Y.K., Cho, S.K., Won, S., Choi, C.B., Kim, T.H., Jun, J.B., et al. Incidence of tuberculosis in rheumatoid arthritis patients using anti-tumor necrosis factor agents following latent tuberculosis infection screening strategies. J Rheum Dis 22 (2015), 223–230.
22. Liao, T.L., Lin, C.H., Chen, Y.M., Chang, C.L., Chen, H.H., Chen, D.Y., Different risk of tuberculosis and efficacy of isoniazid prophylaxis in rheumatoid arthritis patients with biologic therapy: a nationwide retrospective cohort study in Taiwan. PLoS One, 11, 2016, e0153217.
23. Denis, B., Lefort, A., Flipo, R.M., Tubach, F., Lemann, M., Ravaud, P., et al. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment. Clin Microbiol Infect 14 (2008), 183–186.
24. Cantini, F., Nannini, C., Niccoli, L., Iannone, F., Delogu, G., Garlaschi, G., et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev 14 (2015), 503–509.
25. Kim, H.W., Kwon, S.R., Jung, K.H., Kim, S.K., Baek, H.J., Seo, M.R., et al. Safety of resuming tumor necrosis factor inhibitors in ankylosing spondylitis patients concomitant with the treatment of active tuberculosis: a retrospective nationwide registry of the Korean Society of Spondyloarthritis Research. PLoS One, 11, 2016, e0153816, 10.1371/journal.pone.0153816 eCollection 2016.
26. Tam, L.S., Leung, C.C., Ying, S.K., Lee, G.K., Yim, C.W., Leung, Y.Y., et al. Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong-the role of TNF blockers in an area of high tuberculosis burden. Clin Exp Rheumatol 28 (2010), 679–685.
27. Tubach, F., Salmon, D., Ravaud, P., Allanore, Y., Goupille, P., Bréban, M., et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60 (2009), 1884–1894.
28. Navarra, S.V., Tang, B., Lu, L., Lin, H.Y., Mok, C.C., Asavatanabodee, P., et al. Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia. Int J Rheum Dis 17 (2014), 291–298.
29. van Vollenhoven, R.F., Emery, P., Bingham, C.O. 3rd, Keystone, E.C., Fleischmann, R.M., Furst, D.E., et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72 (2013), 1496–1502.
30. Cantini, F., Prignano, F., Goletti, D., Restarting biologics and management of patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment. J Rheumatol Suppl 91 (2014), 78–82.